Relmada Therapeutics, Inc.
RLMD
$4.80
$0.051.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 32.22% | 4.11% | -96.88% | -2.28% | 43.81% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -41.46% | -1.67% | 18.48% | 4.40% | -19.30% |
| Change in Net Operating Assets | 530.91% | -119.60% | 559.26% | -989.16% | 100.52% |
| Cash from Operations | 36.24% | -3.23% | -117.14% | -5.00% | 64.57% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 113.00% | -75.78% | -1,239.19% | 1.12% | -56.52% |
| Cash from Investing | 113.00% | -75.78% | -1,239.19% | 1.12% | -56.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.94% | 70.87% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -90.45% | -- | -- | 100.00% | -- |
| Cash from Financing | -104.10% | 67.21% | -- | 100.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -75.19% | 197.33% | 6,691.32% | -84.72% | 107.52% |